John Johnson - Oct 5, 2021 Form 4/A - Amendment Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Oct 5, 2021
Transactions value $
$46,571
Form type
4/A - Amendment
Date filed
10/8/2021, 06:29 PM
Date Of Original Report
Oct 5, 2021
Previous filing
Oct 5, 2021
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award +478K 478K Oct 5, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Award +10.4K 10.4K Oct 5, 2021 Common Stock 10.4K $22.39 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award +31.4K 31.4K Oct 5, 2021 Common Stock 31.4K $7.02 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award +31.4K 31.4K Oct 5, 2021 Common Stock 31.4K $5.62 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award +31.4K 31.4K Oct 5, 2021 Common Stock 31.4K $9.89 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award +216K 216K Oct 5, 2021 Common Stock 216K $1.99 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award +68.6K 68.6K Oct 5, 2021 Common Stock 68.6K $2.43 Direct F2, F3
transaction XERS Stock Option (Right to Buy) Award $46.6K +19.7K $2.37 19.7K Oct 5, 2021 Common Stock 19.7K $2.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.
F2 At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.
F3 These options are fully vested as of the date hereof.
F4 One third of these options shall vest in equal annual installments until the third anniversary of the date of grant.